Pyxis Oncology, Inc. (NASDAQ:PYXS) is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. Despite its promising mission, the stock is currently trading at $2.91, with a target price of $2.06. This suggests a potential downside of -29.04%, leading analysts to adopt a pessimistic outlook and exclude it from coverage.
Comparatively, Zura Bio Limited (ZURA) is trading at $4.34, with a target price of $2.35, indicating a potential downside of -45.83%. This significant gap between the current and target prices suggests a more cautious approach for investors considering ZURA.
Elevation Oncology, Inc. (ELEV) trades at $0.365, with a target price of $0.32, showing a potential downside of -12.32%. Despite this, ELEV is noted for its high growth potential, making it a more attractive option among its peers, as highlighted by its smaller downside percentage.
Biomea Fusion, Inc. (BMEA) is trading at $1.68, with a target price of $1.37, indicating a potential downside of -18.38%. This positions BMEA as a less risky investment compared to ZURA but still presents a notable downside risk.
Werewolf Therapeutics, Inc. (HOWL) trades at $1.88, with a target price of $1.61, showing a potential downside of -14.24%. While HOWL's downside is less than that of ZURA and BMEA, it still presents a risk, making ELEV's smaller downside and growth potential more appealing.
